Hyponatremia in Cirrhosis
Authors:
- 9 April 2015
- book chapter
- Published by Springer Nature
- p. 131-139
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- 648 HYPONATREMIA IS A MAJOR FACTOR OF THE IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CIRRHOSIS AND ASCITESJournal of Hepatology, 2012
- Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentrationLiver International, 2010
- Pathogenetic mechanisms of hepatic encephalopathyGut, 2008
- Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremiaHepatology, 2008
- MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantationGut, 2007
- Physiology and pathophysiology of renal aquaporinsSeminars in Nephrology, 2001
- HyponatremiaNew England Journal of Medicine, 2000
- The Urine/Plasma Electrolyte Ratio: A Predictive Guide to Water RestrictionThe American Journal of the Medical Sciences, 2000
- Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites.Gut, 1990